Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates

被引:286
作者
Gangjee, Aleem [1 ]
Zeng, Yibin
Talreja, Tina
McGuire, John J.
Kisliuk, Roy L.
Queener, Sherry F.
机构
[1] Duquesne Univ, Div Med Chem, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA
[2] Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA
[3] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA
[4] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA
关键词
CCRF-CEM CELLS; DIHYDROFOLATE-REDUCTASE; METHOTREXATE-RESISTANT; THYMIDYLATE SYNTHASE; POTENTIAL ANTITUMOR; FOLIC-ACID; INHIBITORS; LYMPHOBLASTS; LEUKEMIA; CULTURE;
D O I
10.1021/jm070165j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The classical antifolate N- {4-[( 2,4- diamino- 5-ethyl-7H- pyrrolo[ 2,3- d] pyrimidin- 6- yl) sulfanyl] benzoyl}- Lglutamic acid ( 2) and 15 nonclassical analogues ( 3- 17) were synthesized as potential dihydrofolate reductase ( DHFR) inhibitors and as antitumor agents. 5- Ethyl- 7H- pyrrolo[ 2,3- d] pyrimidine- 2,4- diamine ( 20) served as the key intermediate to which various aryl thiols and a heteroaryl thiol were appended at the 6- position via an oxidative addition reaction. The classical analogue 2 was synthesized by coupling the benzoic acid derivative 18 with diethyl L- glutamate followed by saponification. The classical compound 2 was an excellent inhibitor of human DHFR ( IC50 = 66 nM) as well as a two digit nanomolar (< 100 nM) inhibitor of the growth of several tumor cells in culture. Some of the nonclassical analogues were potent and selective inhibitors of DHFR from two pathogens ( Toxoplasma gondii and Mycobacterium avium) that cause opportunistic infections in patients with compromised immune systems.
引用
收藏
页码:3046 / 3053
页数:8
相关论文
共 20 条
[1]   THE RENEWED POTENTIAL FOR FOLATE ANTAGONISTS IN CONTEMPORARY CANCER-CHEMOTHERAPY [J].
BERMAN, EM ;
WERBEL, LM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :479-485
[2]  
FOLEY GE, 1965, CANCER-AM CANCER SOC, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[3]  
2-J
[4]  
Gangjee A, 1996, CURR PHARM DESIGN, V2, P263
[5]   Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents [J].
Gangjee, A ;
Lin, X ;
Kisliuk, RL ;
McGuire, JJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7215-7222
[6]   Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors [J].
Gangjee, A ;
Lin, X ;
Queener, SF .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3689-3692
[7]   Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate [J].
Gangjee, A ;
Zeng, YB ;
McGuire, JJ ;
Kisliuk, RL .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) :1942-1948
[8]   2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase [J].
Gangjee, A ;
Mavandadi, F ;
Kisliuk, RL ;
McGuire, JJ ;
Queener, SF .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (23) :4563-4568
[9]  
GRINDEY GB, 1979, MOL PHARMACOL, V16, P601
[10]  
HAKALA MT, 1959, J BIOL CHEM, V234, P126